Correlation Between Inozyme Pharma and Design Therapeutics
Can any of the company-specific risk be diversified away by investing in both Inozyme Pharma and Design Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Inozyme Pharma and Design Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Inozyme Pharma and Design Therapeutics, you can compare the effects of market volatilities on Inozyme Pharma and Design Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Inozyme Pharma with a short position of Design Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Inozyme Pharma and Design Therapeutics.
Diversification Opportunities for Inozyme Pharma and Design Therapeutics
-0.47 | Correlation Coefficient |
Very good diversification
The 3 months correlation between Inozyme and Design is -0.47. Overlapping area represents the amount of risk that can be diversified away by holding Inozyme Pharma and Design Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Design Therapeutics and Inozyme Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Inozyme Pharma are associated (or correlated) with Design Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Design Therapeutics has no effect on the direction of Inozyme Pharma i.e., Inozyme Pharma and Design Therapeutics go up and down completely randomly.
Pair Corralation between Inozyme Pharma and Design Therapeutics
Given the investment horizon of 90 days Inozyme Pharma is expected to generate 0.89 times more return on investment than Design Therapeutics. However, Inozyme Pharma is 1.13 times less risky than Design Therapeutics. It trades about 0.05 of its potential returns per unit of risk. Design Therapeutics is currently generating about 0.01 per unit of risk. If you would invest 141.00 in Inozyme Pharma on August 23, 2024 and sell it today you would earn a total of 126.00 from holding Inozyme Pharma or generate 89.36% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Very Weak |
| Accuracy | 99.8% |
| Values | Daily Returns |
Inozyme Pharma vs. Design Therapeutics
Performance |
| Timeline |
| Inozyme Pharma |
| Design Therapeutics |
Inozyme Pharma and Design Therapeutics Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Inozyme Pharma and Design Therapeutics
The main advantage of trading using opposite Inozyme Pharma and Design Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Inozyme Pharma position performs unexpectedly, Design Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Design Therapeutics will offset losses from the drop in Design Therapeutics' long position.| Inozyme Pharma vs. Kiora Pharmaceuticals | Inozyme Pharma vs. ZyVersa Therapeutics | Inozyme Pharma vs. Sonnet Biotherapeutics Holdings | Inozyme Pharma vs. Zura Bio Limited |
| Design Therapeutics vs. Kiora Pharmaceuticals | Design Therapeutics vs. ZyVersa Therapeutics | Design Therapeutics vs. Sonnet Biotherapeutics Holdings | Design Therapeutics vs. Zura Bio Limited |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Other Complementary Tools
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |